APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

PCSK9 Inhibitors

Compare research editions
View pricing & licenses

Selected research

Industry Research

PCSK9 Inhibitors Industry Research Report 2026

Report ID 174022680520 December 2025128 pages

Choose your research edition.

Industry ResearchPCSK9 Inhibitors Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal PCSK9 Inhibitors Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal PCSK9 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PCSK9 Inhibitors Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal PCSK9 Inhibitors Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global PCSK9 Inhibitors market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for PCSK9 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for PCSK9 Inhibitors is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for PCSK9 Inhibitors is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of PCSK9 Inhibitors include Sanofi, Novartis, Merck, Roche, Eli Lilly, Pfizer, Daiichi Sankyo, Amgen and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global PCSK9 Inhibitors market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

PCSK9 Inhibitors Market by Company

Sanofi

Novartis

Merck

Roche

Eli Lilly

Pfizer

Daiichi Sankyo

Amgen

AstraZeneca

Ionis Pharmaceuticals

Cyon Therapeutics

BMS

Alnylam

Affiris

PCSK9 Inhibitors Segment by Type

Praluent(Alirocumab)

Bococizumab

Epatha(Evolocumab)

Others

PCSK9 Inhibitors Segment by Application

Clinical Application

Drug Development

Other

PCSK9 Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PCSK9 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PCSK9 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PCSK9 Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of PCSK9 Inhibitors manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of PCSK9 Inhibitors by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of PCSK9 Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global PCSK9 Inhibitors Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global PCSK9 Inhibitors Sales (k units) of Manufacturers (2021-2026) Table 7. Global PCSK9 Inhibitors Sales Market Share by Manufacturers (2021-2026) Table 8. Global PCSK9 Inhibitors Revenue of Manufacturers (2021-2026) Table 9. Global PCSK9 Inhibitors Revenue Share by Manufacturers (2021-2026) Table 10. Global Market PCSK9 Inhibitors Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global PCSK9 Inhibitors Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of PCSK9 Inhibitors, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of PCSK9 Inhibitors, Product Type & Application Table 14. Global PCSK9 Inhibitors Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global PCSK9 Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Sanofi Company Information Table 19. Sanofi Business Overview Table 20. Sanofi PCSK9 Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Sanofi PCSK9 Inhibitors Product Portfolio Table 22. Sanofi Recent Developments Table 23. Novartis Company Information Table 24. Novartis Business Overview Table 25. Novartis PCSK9 Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Novartis PCSK9 Inhibitors Product Portfolio Table 27. Novartis Recent Developments Table 28. Merck Company Information Table 29. Merck Business Overview Table 30. Merck PCSK9 Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Merck PCSK9 Inhibitors Product Portfolio Table 32. Merck Recent Developments Table 33. Roche Company Information Table 34. Roche Business Overview Table 35. Roche PCSK9 Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Roche PCSK9 Inhibitors Product Portfolio Table 37. Roche Recent Developments Table 38. Eli Lilly Company Information Table 39. Eli Lilly Business Overview Table 40. Eli Lilly PCSK9 Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Eli Lilly PCSK9 Inhibitors Product Portfolio Table 42. Eli Lilly Recent Developments Table 43. Pfizer Company Information Table 44. Pfizer Business Overview Table 45. Pfizer PCSK9 Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Pfizer PCSK9 Inhibitors Product Portfolio Table 47. Pfizer Recent Developments Table 48. Daiichi Sankyo Company Information Table 49. Daiichi Sankyo Business Overview Table 50. Daiichi Sankyo PCSK9 Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Daiichi Sankyo PCSK9 Inhibitors Product Portfolio Table 52. Daiichi Sankyo Recent Developments Table 53. Amgen Company Information Table 54. Amgen Business Overview Table 55. Amgen PCSK9 Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Amgen PCSK9 Inhibitors Product Portfolio Table 57. Amgen Recent Developments Table 58. AstraZeneca Company Information Table 59. AstraZeneca Business Overview Table 60. AstraZeneca PCSK9 Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. AstraZeneca PCSK9 Inhibitors Product Portfolio Table 62. AstraZeneca Recent Developments Table 63. Ionis Pharmaceuticals Company Information Table 64. Ionis Pharmaceuticals Business Overview Table 65. Ionis Pharmaceuticals PCSK9 Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Ionis Pharmaceuticals PCSK9 Inhibitors Product Portfolio Table 67. Ionis Pharmaceuticals Recent Developments Table 68. Cyon Therapeutics Company Information Table 69. Cyon Therapeutics Business Overview Table 70. Cyon Therapeutics PCSK9 Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Cyon Therapeutics PCSK9 Inhibitors Product Portfolio Table 72. Cyon Therapeutics Recent Developments Table 73. BMS Company Information Table 74. BMS Business Overview Table 75. BMS PCSK9 Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. BMS PCSK9 Inhibitors Product Portfolio Table 77. BMS Recent Developments Table 78. Alnylam Company Information Table 79. Alnylam Business Overview Table 80. Alnylam PCSK9 Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Alnylam PCSK9 Inhibitors Product Portfolio Table 82. Alnylam Recent Developments Table 83. Affiris Company Information Table 84. Affiris Business Overview Table 85. Affiris PCSK9 Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Affiris PCSK9 Inhibitors Product Portfolio Table 87. Affiris Recent Developments Table 88. Global PCSK9 Inhibitors Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 89. Global PCSK9 Inhibitors Sales by Region (2021-2026) & (k units) Table 90. Global PCSK9 Inhibitors Sales Market Share by Region (2021-2026) Table 91. Global PCSK9 Inhibitors Sales by Region (2027-2032) & (k units) Table 92. Global PCSK9 Inhibitors Sales Market Share by Region (2027-2032) Table 93. Global PCSK9 Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 94. Global PCSK9 Inhibitors Revenue Market Share by Region (2021-2026) Table 95. Global PCSK9 Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 96. Global PCSK9 Inhibitors Revenue Market Share by Region (2027-2032) Table 97. North America PCSK9 Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. North America PCSK9 Inhibitors Sales by Country (2021-2026) & (k units) Table 99. North America PCSK9 Inhibitors Sales by Country (2027-2032) & (k units) Table 100. North America PCSK9 Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 101. North America PCSK9 Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 102. Europe PCSK9 Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Europe PCSK9 Inhibitors Sales by Country (2021-2026) & (k units) Table 104. Europe PCSK9 Inhibitors Sales by Country (2027-2032) & (k units) Table 105. Europe PCSK9 Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 106. Europe PCSK9 Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 107. Asia Pacific PCSK9 Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Asia Pacific PCSK9 Inhibitors Sales by Country (2021-2026) & (k units) Table 109. Asia Pacific PCSK9 Inhibitors Sales by Country (2027-2032) & (k units) Table 110. Asia Pacific PCSK9 Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 111. Asia Pacific PCSK9 Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 112. South America PCSK9 Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. South America PCSK9 Inhibitors Sales by Country (2021-2026) & (k units) Table 114. South America PCSK9 Inhibitors Sales by Country (2027-2032) & (k units) Table 115. South America PCSK9 Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 116. South America PCSK9 Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 117. Middle East and Africa PCSK9 Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Middle East and Africa PCSK9 Inhibitors Sales by Country (2021-2026) & (k units) Table 119. Middle East and Africa PCSK9 Inhibitors Sales by Country (2027-2032) & (k units) Table 120. Middle East and Africa PCSK9 Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 121. Middle East and Africa PCSK9 Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 122. Global PCSK9 Inhibitors Sales by Type (2021-2026) & (k units) Table 123. Global PCSK9 Inhibitors Sales by Type (2027-2032) & (k units) Table 124. Global PCSK9 Inhibitors Sales Market Share by Type (2021-2026) Table 125. Global PCSK9 Inhibitors Sales Market Share by Type (2027-2032) Table 126. Global PCSK9 Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 127. Global PCSK9 Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 128. Global PCSK9 Inhibitors Revenue Market Share by Type (2021-2026) Table 129. Global PCSK9 Inhibitors Revenue Market Share by Type (2027-2032) Table 130. Global PCSK9 Inhibitors Price by Type (2021-2026) & (US$/unit) Table 131. Global PCSK9 Inhibitors Price by Type (2027-2032) & (US$/unit) Table 132. Global PCSK9 Inhibitors Sales by Application (2021-2026) & (k units) Table 133. Global PCSK9 Inhibitors Sales by Application (2027-2032) & (k units) Table 134. Global PCSK9 Inhibitors Sales Market Share by Application (2021-2026) Table 135. Global PCSK9 Inhibitors Sales Market Share by Application (2027-2032) Table 136. Global PCSK9 Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 137. Global PCSK9 Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 138. Global PCSK9 Inhibitors Revenue Market Share by Application (2021-2026) Table 139. Global PCSK9 Inhibitors Revenue Market Share by Application (2027-2032) Table 140. Global PCSK9 Inhibitors Price by Application (2021-2026) & (US$/unit) Table 141. Global PCSK9 Inhibitors Price by Application (2027-2032) & (US$/unit) Table 142. Key Raw Materials Table 143. Raw Materials Key Suppliers Table 144. PCSK9 Inhibitors Distributors List Table 145. PCSK9 Inhibitors Customers List Table 146. PCSK9 Inhibitors Industry Trends Table 147. PCSK9 Inhibitors Industry Drivers Table 148. PCSK9 Inhibitors Industry Restraints Table 149. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. PCSK9 Inhibitors Product Image Figure 5. Global PCSK9 Inhibitors Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global PCSK9 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 7. Global PCSK9 Inhibitors Sales (2021-2032) & (k units) Figure 8. Global PCSK9 Inhibitors Average Price (US$/unit) & (2021-2032) Figure 9. Praluent(Alirocumab) Product Image Figure 10. Bococizumab Product Image Figure 11. Epatha(Evolocumab) Product Image Figure 12. Others Product Image Figure 13. Clinical Application Product Image Figure 14. Drug Development Product Image Figure 15. Other Product Image Figure 16. Global PCSK9 Inhibitors Revenue Share by Manufacturers in 2025 Figure 17. Global Manufacturers of PCSK9 Inhibitors, Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 PCSK9 Inhibitors Players Market Share by Revenue in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global PCSK9 Inhibitors Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 21. Global PCSK9 Inhibitors Sales by Region in 2025 Figure 22. Global PCSK9 Inhibitors Revenue by Region in 2025 Figure 23. North America PCSK9 Inhibitors Market Size by Country in 2025 Figure 24. North America PCSK9 Inhibitors Sales Market Share by Country (2021-2032) Figure 25. North America PCSK9 Inhibitors Revenue Market Share by Country (2021-2032) Figure 26. United States PCSK9 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Canada PCSK9 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Mexico PCSK9 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Europe PCSK9 Inhibitors Market Size by Country in 2025 Figure 30. Europe PCSK9 Inhibitors Sales Market Share by Country (2021-2032) Figure 31. Europe PCSK9 Inhibitors Revenue Market Share by Country (2021-2032) Figure 32. Germany PCSK9 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. France PCSK9 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. U.K. PCSK9 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Italy PCSK9 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Russia PCSK9 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Spain PCSK9 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Netherlands PCSK9 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Switzerland PCSK9 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Sweden PCSK9 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Poland PCSK9 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Asia Pacific PCSK9 Inhibitors Market Size by Country in 2025 Figure 43. Asia Pacific PCSK9 Inhibitors Sales Market Share by Country (2021-2032) Figure 44. Asia Pacific PCSK9 Inhibitors Revenue Market Share by Country (2021-2032) Figure 45. China PCSK9 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Japan PCSK9 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. South Korea PCSK9 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. India PCSK9 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Australia PCSK9 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Taiwan PCSK9 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia PCSK9 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia PCSK9 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. South America PCSK9 Inhibitors Market Size by Country in 2025 Figure 54. South America PCSK9 Inhibitors Sales Market Share by Country (2021-2032) Figure 55. South America PCSK9 Inhibitors Revenue Market Share by Country (2021-2032) Figure 56. Brazil PCSK9 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Argentina PCSK9 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Chile PCSK9 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Middle East and Africa PCSK9 Inhibitors Market Size by Country in 2025 Figure 60. Middle East and Africa PCSK9 Inhibitors Sales Market Share by Country (2021-2032) Figure 61. Middle East and Africa PCSK9 Inhibitors Revenue Market Share by Country (2021-2032) Figure 62. Egypt PCSK9 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. South Africa PCSK9 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Israel PCSK9 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Türkiye PCSK9 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. GCC Countries PCSK9 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Global PCSK9 Inhibitors Sales Market Share by Type (2021-2032) Figure 68. Global PCSK9 Inhibitors Revenue Market Share by Type (2021-2032) Figure 69. Global PCSK9 Inhibitors Price (US$/unit) by Type (2021-2032) Figure 70. Global PCSK9 Inhibitors Sales Market Share by Application (2021-2032) Figure 71. Global PCSK9 Inhibitors Revenue Market Share by Application (2021-2032) Figure 72. Global PCSK9 Inhibitors Price (US$/unit) by Application (2021-2032) Figure 73. PCSK9 Inhibitors Value Chain Figure 74. PCSK9 Inhibitors Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. PCSK9 Inhibitors Industry Opportunities and Challenges

Scope & coverage.

Types
  • Praluent(Alirocumab)
  • Bococizumab
  • Epatha(Evolocumab)
  • Others
Applications
  • Clinical Application
  • Drug Development
  • Other
Companies covered
  • Sanofi
  • Novartis
  • Merck
  • Roche
  • Eli Lilly
  • Pfizer
  • Daiichi Sankyo
  • Amgen
  • AstraZeneca
  • Ionis Pharmaceuticals
  • Cyon Therapeutics
  • BMS
  • Alnylam
  • Affiris

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global PCSK9 Inhibitors Market Size (2021-2032)
  4. 2.2.2 Global PCSK9 Inhibitors Sales (2021-2032)
  5. 2.2.3 Global PCSK9 Inhibitors Market Average Price (2021-2032)
  6. 2.3 PCSK9 Inhibitors by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Praluent(Alirocumab)
  9. 2.3.3 Bococizumab
  10. 2.3.4 Epatha(Evolocumab)
  11. 2.3.5 Others
  12. 2.4 PCSK9 Inhibitors by Application
  13. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  14. 2.4.2 Clinical Application
  15. 2.4.3 Drug Development
  16. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global PCSK9 Inhibitors Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global PCSK9 Inhibitors Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global PCSK9 Inhibitors Revenue of Manufacturers (2021-2026)
  4. 3.4 Global PCSK9 Inhibitors Average Price by Manufacturers (2021-2026)
  5. 3.5 Global PCSK9 Inhibitors Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of PCSK9 Inhibitors, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of PCSK9 Inhibitors, Product Type & Application
  8. 3.8 Global Manufacturers of PCSK9 Inhibitors, Established Date
  9. 3.9 Global PCSK9 Inhibitors Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Sanofi
  2. 4.1.1 Sanofi Company Information
  3. 4.1.2 Sanofi Business Overview
  4. 4.1.3 Sanofi PCSK9 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Sanofi PCSK9 Inhibitors Product Portfolio
  6. 4.1.5 Sanofi Recent Developments
  7. 4.2 Novartis
  8. 4.2.1 Novartis Company Information
  9. 4.2.2 Novartis Business Overview
  10. 4.2.3 Novartis PCSK9 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Novartis PCSK9 Inhibitors Product Portfolio
  12. 4.2.5 Novartis Recent Developments
  13. 4.3 Merck
  14. 4.3.1 Merck Company Information
  15. 4.3.2 Merck Business Overview
  16. 4.3.3 Merck PCSK9 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Merck PCSK9 Inhibitors Product Portfolio
  18. 4.3.5 Merck Recent Developments
  19. 4.4 Roche
  20. 4.4.1 Roche Company Information
  21. 4.4.2 Roche Business Overview
  22. 4.4.3 Roche PCSK9 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Roche PCSK9 Inhibitors Product Portfolio
  24. 4.4.5 Roche Recent Developments
  25. 4.5 Eli Lilly
  26. 4.5.1 Eli Lilly Company Information
  27. 4.5.2 Eli Lilly Business Overview
  28. 4.5.3 Eli Lilly PCSK9 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Eli Lilly PCSK9 Inhibitors Product Portfolio
  30. 4.5.5 Eli Lilly Recent Developments
  31. 4.6 Pfizer
  32. 4.6.1 Pfizer Company Information
  33. 4.6.2 Pfizer Business Overview
  34. 4.6.3 Pfizer PCSK9 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Pfizer PCSK9 Inhibitors Product Portfolio
  36. 4.6.5 Pfizer Recent Developments
  37. 4.7 Daiichi Sankyo
  38. 4.7.1 Daiichi Sankyo Company Information
  39. 4.7.2 Daiichi Sankyo Business Overview
  40. 4.7.3 Daiichi Sankyo PCSK9 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Daiichi Sankyo PCSK9 Inhibitors Product Portfolio
  42. 4.7.5 Daiichi Sankyo Recent Developments
  43. 4.8 Amgen
  44. 4.8.1 Amgen Company Information
  45. 4.8.2 Amgen Business Overview
  46. 4.8.3 Amgen PCSK9 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Amgen PCSK9 Inhibitors Product Portfolio
  48. 4.8.5 Amgen Recent Developments
  49. 4.9 AstraZeneca
  50. 4.9.1 AstraZeneca Company Information
  51. 4.9.2 AstraZeneca Business Overview
  52. 4.9.3 AstraZeneca PCSK9 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 AstraZeneca PCSK9 Inhibitors Product Portfolio
  54. 4.9.5 AstraZeneca Recent Developments
  55. 4.10 Ionis Pharmaceuticals
  56. 4.10.1 Ionis Pharmaceuticals Company Information
  57. 4.10.2 Ionis Pharmaceuticals Business Overview
  58. 4.10.3 Ionis Pharmaceuticals PCSK9 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Ionis Pharmaceuticals PCSK9 Inhibitors Product Portfolio
  60. 4.10.5 Ionis Pharmaceuticals Recent Developments
  61. 4.11 Cyon Therapeutics
  62. 4.11.1 Cyon Therapeutics Company Information
  63. 4.11.2 Cyon Therapeutics Business Overview
  64. 4.11.3 Cyon Therapeutics PCSK9 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Cyon Therapeutics PCSK9 Inhibitors Product Portfolio
  66. 4.11.5 Cyon Therapeutics Recent Developments
  67. 4.12 BMS
  68. 4.12.1 BMS Company Information
  69. 4.12.2 BMS Business Overview
  70. 4.12.3 BMS PCSK9 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 BMS PCSK9 Inhibitors Product Portfolio
  72. 4.12.5 BMS Recent Developments
  73. 4.13 Alnylam
  74. 4.13.1 Alnylam Company Information
  75. 4.13.2 Alnylam Business Overview
  76. 4.13.3 Alnylam PCSK9 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Alnylam PCSK9 Inhibitors Product Portfolio
  78. 4.13.5 Alnylam Recent Developments
  79. 4.14 Affiris
  80. 4.14.1 Affiris Company Information
  81. 4.14.2 Affiris Business Overview
  82. 4.14.3 Affiris PCSK9 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Affiris PCSK9 Inhibitors Product Portfolio
  84. 4.14.5 Affiris Recent Developments
5 Global PCSK9 Inhibitors Market Scenario by Region
  1. 5.1 Global PCSK9 Inhibitors Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global PCSK9 Inhibitors Sales by Region: 2021-2032
  3. 5.2.1 Global PCSK9 Inhibitors Sales by Region: 2021-2026
  4. 5.2.2 Global PCSK9 Inhibitors Sales by Region: 2027-2032
  5. 5.3 Global PCSK9 Inhibitors Revenue by Region: 2021-2032
  6. 5.3.1 Global PCSK9 Inhibitors Revenue by Region: 2021-2026
  7. 5.3.2 Global PCSK9 Inhibitors Revenue by Region: 2027-2032
  8. 5.4 North America PCSK9 Inhibitors Market Facts & Figures by Country
  9. 5.4.1 North America PCSK9 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America PCSK9 Inhibitors Sales by Country (2021-2032)
  11. 5.4.3 North America PCSK9 Inhibitors Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe PCSK9 Inhibitors Market Facts & Figures by Country
  16. 5.5.1 Europe PCSK9 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe PCSK9 Inhibitors Sales by Country (2021-2032)
  18. 5.5.3 Europe PCSK9 Inhibitors Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific PCSK9 Inhibitors Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific PCSK9 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific PCSK9 Inhibitors Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific PCSK9 Inhibitors Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America PCSK9 Inhibitors Market Facts & Figures by Country
  41. 5.7.1 South America PCSK9 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America PCSK9 Inhibitors Sales by Country (2021-2032)
  43. 5.7.3 South America PCSK9 Inhibitors Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa PCSK9 Inhibitors Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa PCSK9 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa PCSK9 Inhibitors Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa PCSK9 Inhibitors Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global PCSK9 Inhibitors Sales by Type (2021-2032)
  2. 6.1.1 Global PCSK9 Inhibitors Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global PCSK9 Inhibitors Sales Market Share by Type (2021-2032)
  4. 6.2 Global PCSK9 Inhibitors Revenue by Type (2021-2032)
  5. 6.2.1 Global PCSK9 Inhibitors Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global PCSK9 Inhibitors Revenue Market Share by Type (2021-2032)
  7. 6.3 Global PCSK9 Inhibitors Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global PCSK9 Inhibitors Sales by Application (2021-2032)
  2. 7.1.1 Global PCSK9 Inhibitors Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global PCSK9 Inhibitors Sales Market Share by Application (2021-2032)
  4. 7.2 Global PCSK9 Inhibitors Revenue by Application (2021-2032)
  5. 7.2.1 Global PCSK9 Inhibitors Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global PCSK9 Inhibitors Revenue Market Share by Application (2021-2032)
  7. 7.3 Global PCSK9 Inhibitors Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 PCSK9 Inhibitors Value Chain Analysis
  2. 8.1.1 PCSK9 Inhibitors Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 PCSK9 Inhibitors Production Mode & Process
  5. 8.2 PCSK9 Inhibitors Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 PCSK9 Inhibitors Distributors
  8. 8.2.3 PCSK9 Inhibitors Customers
9 Global PCSK9 Inhibitors Analyzing Market Dynamics
  1. 9.1 PCSK9 Inhibitors Industry Trends
  2. 9.2 PCSK9 Inhibitors Industry Drivers
  3. 9.3 PCSK9 Inhibitors Industry Opportunities and Challenges
  4. 9.4 PCSK9 Inhibitors Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst